| | | | | | | | | | |
|
|
| Dockets Entered
On July 7, 2005
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1989V-0161
|
| VARIANCE FOR GRAND COULEE DAM LASER SHOW
|
|
|
| 1992V-0087
|
| Laser effects for 'Fantasmic' show
|
|
|
| 1999V-1630
|
| Laser Light Show
|
|
|
| 2000V-1453
|
| Laser Light Show (Golden Dreams Laser Special Effects)
|
|
|
| 2000V-1576
|
| AN/PEQ-2A, Target Pointer-Illuminator/Aiming Light
|
|
|
| 2002P-0135
|
| Orally-Administered Levothyroxine Sodium all NDAs & ANDAs
|
|
|
| 2002V-0041
|
| Laser Light Show
|
|
|
| 2002V-0265
|
| Laser Light Show
|
|
|
| 2002V-0420
|
| Laser light show
|
|
|
| 2003V-0042
|
| Laser Light Show Projector
|
|
|
| 2004Q-0083
|
| Qualified health claim (QHC): Green Tea and Reduced Risk of Cancer
|
|
|
| 2005N-0147
|
| Sprout Safety Public Meeting
|
|
|
| 2005P-0076
|
| OxyContin and Paladone removal from market and label changes limiting indications to severe chronic pain
|
|
|
| 2005P-0273
|
| Add Calcium to the Mandatory List
|
|
|
| 2005P-0275
|
| Request for a change to a listed drug to allow submission of an Abbreviated New Drug Application for Lidocaine Hydrochloride Injection USP, 2%.
|
|
|
| 2005Q-0211
|
| Health Claim Notification: Whole Grains and Coronary Heart Disease
|
|
|
| 1989V-0161
|
| VARIANCE FOR GRAND COULEE DAM LASER SHOW
|
|
|
| VRA
6
|
| HFZ-200 to U S Bureau of Reclamation
|
| Vol #:
|
| 1
|
|
|
| 1992V-0087
|
| Laser effects for 'Fantasmic' show
|
|
|
| VRA
6
|
| HFZ-200 to Walt Disney Productions
|
| Vol #:
|
| 1
|
|
|
| 1999V-1630
|
| Laser Light Show
|
|
|
| VRA
4
|
| HFZ-200 to Visual FX (Formerly Laser Laser Services)
|
| Vol #:
|
| 1
|
|
|
| 2000V-1453
|
| Laser Light Show (Golden Dreams Laser Special Effects)
|
|
|
| VRA
2
|
| HFZ-200 to Walk Disney Productions
|
| Vol #:
|
| 1
|
|
|
| 2000V-1576
|
| AN/PEQ-2A, Target Pointer-Illuminator/Aiming Light
|
|
|
| VRA
4
|
| HFZ-200 to Insight Technology Inc
|
| Vol #:
|
| 1
|
|
|
| 2002P-0135
|
| Orally-Administered Levothyroxine Sodium all NDAs & ANDAs
|
|
|
| M
8
|
| HFD-630 Regarding ANDA 76-752
|
| Vol #:
|
| 1
|
|
|
| 2002V-0041
|
| Laser Light Show
|
|
|
| VRA
2
|
| HFZ-200 to Laser Wizardry East
|
| Vol #:
|
| 1
|
|
|
| 2002V-0265
|
| Laser Light Show
|
|
| | | | | | | | |
|
|
| VRA
2
|
| HFZ-200 to Canobie Lake Park
|
| Vol #:
|
| 1
|
|
|
| 2002V-0420
|
| Laser light show
|
|
|
| VRA
2
|
| HFZ-200 to Lasergrace Incorporated
|
| Vol #:
|
| 1
|
|
|
| 2003V-0042
|
| Laser Light Show Projector
|
|
|
| VRA
2
|
| HFZ-200 to Laserwurx, LLC
|
| Vol #:
|
| 1
|
|
|
| 2004Q-0083
|
| Qualified health claim (QHC): Green Tea and Reduced Risk of Cancer
|
|
|
| LET
12
Attachment
|
| Fleminger Inc
|
| Vol #:
|
| 8
|
|
|
| LET
13
|
| Fleminger Inc
|
| Vol #:
|
| 8
|
|
|
| LET
14
|
| Fleminger Inc
|
| Vol #:
|
| 8
|
|
|
| LET
15
|
| Fleminger Inc
|
| Vol #:
|
| 8
|
|
|
| PDN
1
|
| HFS-1 to Fleminger Inc
|
| Vol #:
|
| 9
|
|
|
| 2005N-0147
|
| Sprout Safety Public Meeting
|
|
|
| TR
1
|
| Transcript of the May 17, 2005 Meeting
|
| Vol #:
|
| 2
|
|
|
| 2005P-0076
|
| OxyContin and Paladone removal from market and label changes limiting indications to severe chronic pain
|
|
| C 2
|
| Form Letter
|
| Vol #:
|
| 2
|
|
|
| 2005P-0273
|
| Add Calcium to the Mandatory List
|
|
|
| ACK
1
|
| HFA-305 to Rutgers University
|
| Vol #:
|
| 1
|
|
|
| ACK 2
|
| Number Not Used
|
| Vol #:
|
| 1
|
|
|
| CP
1
|
| Rutgers University
|
| Vol #:
|
| 1
|
|
|
| 2005P-0275
|
| Request for a change to a listed drug to allow submission of an Abbreviated New Drug Application for Lidocaine Hydrochloride Injection USP, 2%.
|
|
|
| CP
1
|
| Taro Pharmaceuticals, U.S.A., Inc.
|
| Vol #:
|
| 1
|
|
|
| WDL
1
|
| HFD-7 to Taro Pharmaceuticals, U.S.A., Inc.
|
| Vol #:
|
| 1
|
|
|
| 2005Q-0211
|
| Health Claim Notification: Whole Grains and Coronary Heart Disease
|
|
|
| C
1
|
| Roman Meal Company
|
| Vol #:
|
| 1
|
|